Japan’s Otsuka Sues Indian Cadila’s U.S. Unit To Block Generic
This article was originally published in PharmAsia News
Executive Summary
Japan-based Otsuka Pharmaceutical has filed suit in a U.S. court to block a unit of Cadila Healthcare of India from making a generic version of Otsuka's Abilify (aripiprazole) for treating schizophrenia. Cadila wants to apply to the U.S. FDA for approval to market a generic, but Otsuka said its patent on the drug does not expire until 2014. The suit named Cadila's U.S. arm, Zydus Pharmaceuticals. (Click here for more